Know Cancer

or
forgot password

Clinical Outcomes in Hereditary Cancer


N/A
N/A
N/A
Open (Enrolling)
Both
Breast Cancer, Pancreatic Cancer

Thank you

Trial Information

Clinical Outcomes in Hereditary Cancer


Compare the clinical characteristics and post-surgical outcomes (overall survival)of
pancreatic cancer patients of Ashkenazi descent with or without germline founder mutations
in BRCA1 or BRCA2 .

Compare the clinical characteristics and outcomes (time to progression) of breast cancer
patients of Ashkenazi descent with or without germline founder mutations in BRCA1 or BRCA2
receiving paclitaxel chemotherapy for metastatic disease.


Inclusion Criteria:



- Included in DB0363-03

- Jewish religious preference at registration

- Archival material available for testing

- Adequate post-surgical follow-up

- Jewish religious preference at registration

- Archival material available for testing

- Adequate follow-up to determine time to progression

Exclusion Criteria:

-Subjects will not be included in the analyses if a DNA sample cannot be obtained.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Retrospective

Outcome Measure:

The overall objective of the protocol is to examine the hypothesis that hereditary cancers are distinct in clinical characteristics and outcome from those that arise in the absence of a known predisposition.

Outcome Time Frame:

2 years

Safety Issue:

Yes

Principal Investigator

Mark Robson, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

06-004

NCT ID:

NCT00580021

Start Date:

January 2006

Completion Date:

January 2014

Related Keywords:

  • Breast Cancer
  • Pancreatic Cancer
  • Ashkenazi ancestry
  • mutations in BRCA1 or BRCA2
  • Breast Cancer
  • Pancreatic Cancer
  • Breast Neoplasms
  • Pancreatic Neoplasms

Name

Location

Memorial Sloan-Kettering Cancer CenterNew York, New York  10021